Solventum (NYSE:SOLV) Stock Rating Upgraded by Wall Street Zen

Solventum (NYSE:SOLV) was upgraded by equities research analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a research report issued on Saturday.

A number of other brokerages also recently commented on SOLV. Mizuho set a $113.00 price objective on shares of Solventum in a research report on Thursday. UBS Group boosted their target price on Solventum from $95.00 to $101.00 and gave the stock a “buy” rating in a research report on Thursday. Weiss Ratings raised Solventum from a “hold (c)” rating to a “hold (c+)” rating in a research note on Friday, July 17th. Wells Fargo & Company cut their target price on Solventum from $83.00 to $70.00 and set an “equal weight” rating for the company in a research note on Wednesday, May 6th. Finally, KeyCorp raised their price target on Solventum from $93.00 to $102.00 and gave the company an “overweight” rating in a report on Thursday. Seven investment analysts have rated the stock with a Buy rating, five have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Solventum presently has an average rating of “Hold” and an average target price of $91.64.

Solventum Stock Up 0.0%

Shares of Solventum stock opened at $83.00 on Friday. The company has a market cap of $14.13 billion, a P/E ratio of 10.15, a PEG ratio of 1.06 and a beta of 0.60. The company has a debt-to-equity ratio of 1.00, a quick ratio of 0.74 and a current ratio of 1.02. Solventum has a one year low of $62.38 and a one year high of $90.00. The firm has a fifty day moving average of $79.40 and a two-hundred day moving average of $74.41.

Solventum (NYSE:SOLV) last released its earnings results on Wednesday, August 5th. The company reported $2.55 EPS for the quarter, topping the consensus estimate of $1.91 by $0.64. The company had revenue of $2.21 billion during the quarter, compared to analysts’ expectations of $2.15 billion. Solventum had a net margin of 17.26% and a return on equity of 25.09%. The business’s revenue was up 2.2% on a year-over-year basis. During the same quarter last year, the business earned $1.69 EPS. Solventum has set its FY 2026 guidance at 7.100-7.200 EPS. On average, analysts forecast that Solventum will post 7.25 earnings per share for the current year.

Institutional Trading of Solventum

A number of large investors have recently made changes to their positions in the stock. Independent Franchise Partners LLP lifted its holdings in Solventum by 19.0% in the 4th quarter. Independent Franchise Partners LLP now owns 15,355,691 shares of the company’s stock valued at $1,216,785,000 after purchasing an additional 2,456,451 shares in the last quarter. State Street Corp grew its holdings in shares of Solventum by 2.0% during the fourth quarter. State Street Corp now owns 6,344,761 shares of the company’s stock worth $502,759,000 after buying an additional 124,490 shares in the last quarter. Davis Selected Advisers raised its position in shares of Solventum by 12.7% in the fourth quarter. Davis Selected Advisers now owns 6,220,072 shares of the company’s stock valued at $492,880,000 after buying an additional 702,461 shares during the last quarter. Boston Partners raised its position in shares of Solventum by 26.1% in the third quarter. Boston Partners now owns 4,630,300 shares of the company’s stock valued at $338,006,000 after buying an additional 959,543 shares during the last quarter. Finally, Geode Capital Management LLC lifted its stake in shares of Solventum by 20.0% during the fourth quarter. Geode Capital Management LLC now owns 4,588,728 shares of the company’s stock valued at $362,375,000 after buying an additional 763,308 shares during the period.

Key Solventum News

Here are the key news stories impacting Solventum this week:

• Positive Sentiment: Q2 results exceeded expectations. Solventum reported adjusted earnings of $2.55 per share versus the $1.91 consensus estimate, while revenue of $2.21 billion also topped forecasts. Organic sales increased 9.5%, and revenue grew 2.2% year over year. Solventum Stock Up as Q2 Earnings & Revenues Beat Estimates
• Positive Sentiment: Management raised 2026 earnings guidance to $7.10-$7.20 per share, above its previous outlook. Strong cash flow and the company’s share-repurchase activity further support investor sentiment, although some of the quarter’s benefit came from ERP implementation timing. Solventum outlines HIS separation and raises 2026 EPS guide
• Positive Sentiment: Analyst conviction strengthened. Piper Sandler raised its target to $105 and maintained an overweight rating; Wedbush lifted its target to $101 with an outperform rating; and Stifel increased its target to $100 with a buy rating. UBS also reiterated its buy recommendation. UBS Remains a Buy on Solventum Corporation
• Positive Sentiment: Software separation could sharpen the company’s focus. Solventum plans to separate its health information systems business, potentially creating a more focused medical-technology company and unlocking value from the remaining operations. Solventum to hive off healthcare software business

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.